Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection

Simply Wall St.2025-12-21

Amneal Pharmaceuticals (AMRX) just secured FDA approval for its 1 mg/mL epinephrine injection in single and multi dose vials, plugging into a critical hospital therapy market with roughly $118 million...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593144817?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2025-12-21 01:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593144817","market":"sg","top_or_hot":-1,"title":"Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection","media":"Simply Wall St.","content":"<div>\n<p>Amneal Pharmaceuticals (AMRX) just secured FDA approval for its 1 mg/mL epinephrine injection in single and multi dose vials, plugging into a critical hospital therapy market with roughly $118 million...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/amneal-pharmaceuticals-amrx-valuation-check-after-fda-approv\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-21 01:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/amneal-pharmaceuticals-amrx-valuation-check-after-fda-approv><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amneal Pharmaceuticals (AMRX) just secured FDA approval for its 1 mg/mL epinephrine injection in single and multi dose vials, plugging into a critical hospital therapy market with roughly $118 million...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/amneal-pharmaceuticals-amrx-valuation-check-after-fda-approv\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/amneal-pharmaceuticals-amrx-valuation-check-after-fda-approv","article_id":"2593144817","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/amneal-pharmaceuticals-amrx-valuation-check-after-fda-approv","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593144817","pubTimestamp":1766251110,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Amneal Pharmaceuticals (AMRX) just secured FDA approval for its 1 mg/mL epinephrine injection in single and multi dose vials, plugging into a critical hospital therapy market with roughly $118 million in U.S. annual sales.\nSee our latest analysis for Amneal Pharmaceuticals.\nThe FDA approval lands as Amneal’s share price sits at $12.57 and recent momentum has been strong, with a roughly 62 percent year to date share price return and a powerful multi year total shareholder return backing the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Amneal Pharmaceuticals(AMRX)：FDA批准新型肾上腺素注射液后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1.5},"content_text":"Amneal Pharmaceuticals (AMRX) just secured FDA approval for its 1 mg/mL epinephrine injection in single and multi dose vials, plugging into a critical hospital therapy market with roughly $118 million in U.S. annual sales. See our latest analysis for Amneal Pharmaceuticals. The FDA approval lands as Amneal’s share price sits at $12.57 and recent momentum has been strong, with a roughly 62 percent year to date share price return and a powerful multi year total shareholder return backing the longer term growth story. If this approval has you rethinking your exposure to healthcare, it could be a moment to explore other opportunities across healthcare stocks and see what else is positioning for the next leg higher. With the share price already up more than 60 percent year to date and only a modest gap to Wall Street’s target, the real question now is whether Amneal still trades at a discount or if the market is already pricing in the next leg of growth. Most Popular Narrative Narrative: 8.9% Undervalued Compared with the last close at $12.57, the most followed narrative sees Amneal’s fair value closer to $13.80, hinting at further upside driven by execution and pipeline momentum.  The fair value estimate has risen slightly to approximately $13.80 from about $13.50. This reflects modest upward revisions to the intrinsic value outlook. The future P/E has risen modestly to around 26.8x from about 26.2x. This signals a slightly higher valuation multiple applied to forward earnings.  Read the complete narrative. Curious what kind of revenue path and margin lift could justify that richer earnings multiple, yet still screen as undervalued versus today’s price, and why consensus thinks this growth story is only getting started, not peaking here. Result: Fair Value of $13.80 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside depends on Amneal avoiding intense U.S. generics price pressure and executing on a differentiated biosimilar and specialty pipeline. Find out about the key risks to this Amneal Pharmaceuticals narrative.  Build Your Own Amneal Pharmaceuticals Narrative If this view does not quite match your own or you prefer to dig into the numbers yourself, you can build a fresh narrative in just a few minutes, Do it your way A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision. Looking for more investment ideas? Before the next move catches you off guard, put the Simply Wall Street Screener to work and line up fresh opportunities that fit your strategy.  Tap into potential mispricings by targeting companies that look attractively valued on future cash flows with these 914 undervalued stocks based on cash flows. Ride powerful tech trends by focusing on innovators transforming industries with these 25 AI penny stocks. Build reliable income streams by zeroing in on companies offering stronger yields through these 13 dividend stocks with yields > 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593144817","isCrawlerRequest":true}